Post-chemotherapy C-reactive protein/albumin ratio predicts prognosis in stage II-III colorectal cancer

Table 1 Clinicopathological characteristics of 445 patients, n (%)

Clinicopathologic characteristics (n = 445)	Result
Age, years, median (range)	61.83 (38-87)
Sex
Female	250 (56.18)
Male	195 (43.82)
Site
Colon	305 (68.54)
Rectum	140 (31.46)
CEA
< 5 ng/mL	255 (57.30)
≥ 5 ng/mL	190 (42.70)
Histologic differentiation
Differentiated	390 (87.64)
Others	55 (12.36)
TNM stage
II	180 (40.45)
III	265 (59.55)

CEA: Carcinoembryonic antigen; TNM: Tumor-node-metastasis.

Table 2 The relationship between the C-reactive protein/albumin ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index and clinicopathological characteristics in II/III patients with colorectal cancer

		Age	Sex		Site		CEA (ng/mL)		TNM
			Female	Male	Colon	Rectum	< 5	≥ 5	II	III
CAR	Low	61.74	95	135	165	65	160	70	95	135
Pre-operation
	High	61.93	105	110	140	75	95	120	85	130
	P value	0.86	0.5266		0.6483		0.0192		0.9999
NLR	Low	62.76	75	70	80	65	95	50	55	90
Pre-operation
	High	61.38	125	175	225	75	160	140	125	175
	P value	0.23	0.4957		0.0874		0.3616		0.2918
PLR	Low	63.38	140	120	155	105	165	95	110	100
Pre-operation
	High	59.65	60	125	150	35	90	95	70	115
	P value	0.0006	0.0054		0.0385		0.1953		0.8268
SII	Low	61.93	30	40	40	30	50	20	40	30
Pre-operation
	High	61.81	170	205	265	110	205	170	140	235
	P value	0.94	0.9999		0.3553		0.3782		0.2359

CEA: Carcinoembryonic antigen; TNM: Tumor-node-metastasis; CAR: C-reactive protein/albumin ratio; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index.

Table 3 The relationship between the C-reactive protein/albumin ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index and clinicopathological characteristics in II/III patients with colorectal cancer

		Age	Sex		Site		CEA (ng/mL)		TNM
			Female	Male	Colon	Rectum	< 5	≥ 5	II	III
CAR	Low	61.44	145	185	235	95	215	115	165	165
Post-adjuvant chemotherapy	High	62.96	55	160	70	45	40	75	15	100
	P value	0.21	0.8102		0.436		0.0148		0.0026
NLR	Low	62.69	115	110	155	70	150	75	105	120
Post-adjuvant chemotherapy	High	60.95	85	135	150	70	105	115	75	145
	P value	0.11	0.2888		0.9999		0.0882		0.282
PLR	Low	61.61	95	110	145	60	120	85	100	105
Post-adjuvant chemotherapy	High	62.02	105	135	160	80	135	105	80	160
	P value	0.71	0.0054		0.0385		0.1953		0.8268
SII	Low	62.66	160	180	230	110	205	135	160	180
Post-adjuvant chemotherapy	High	59.14	40	65	75	30	150	55	20	85
	P value	0.01	0.6168		0.7954		0.3246		0.0244

CEA: Carcinoembryonic antigen; TNM: Tumor-node-metastasis; CAR: C-reactive protein/albumin ratio; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index.